<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153410</url>
  </required_header>
  <id_info>
    <org_study_id>J1766</org_study_id>
    <secondary_id>IRB00130267</secondary_id>
    <nct_id>NCT03153410</nct_id>
  </id_info>
  <brief_title>Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas</brief_title>
  <official_title>A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody&#xD;
      that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and IMC-CS4&#xD;
      (LY3022855) (an antibody that blocks a molecule called CSF1-R which prevents the bodies&#xD;
      ability to fight cancer) is effective (anti-tumor activity) and safe in patients with&#xD;
      borderline resectable pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD8 T cell density in the primary tumor after neoadjuvant administration of combination immunotherapy by immunohistochemistry (IHC)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) by immune-related RECIST criteria (irRC)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical resectability rate of borderline resectable pancreatic cancer (BRPC)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic response rate of patients with BRPC</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.&#xD;
Other Names:&#xD;
Cytoxan CY</description>
    <arm_group_label>Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4</arm_group_label>
    <other_name>CY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVAX</intervention_name>
    <description>5E8 cells is to be administered one day after CY, pembrolizumab, and IMC-CS4/ LY3022855 for a total of eight doses.&#xD;
Other Names:&#xD;
Pancreatic cancer vaccine Panc 10.05 pcDNA1/GM-Neo, Panc 6.03 pcDNA1/GM-Neo</description>
    <arm_group_label>Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4</arm_group_label>
    <other_name>Panc 10.05 pcDNA1/GM-Neo, Panc 6.03 pcDNA1/GM-Neo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 18 doses.&#xD;
Other Names:&#xD;
MK-3475 KEYTRUDA</description>
    <arm_group_label>Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4</arm_group_label>
    <other_name>MK-3475, KEYTRUDAÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMC-CS4</intervention_name>
    <description>75 mg for dose level 1 and 100 mg at dose level 2 will be administered (Day 1, Day 8 and Day 15) as a 30 minute(s) IV infusion one day prior to GVAX pancreas vaccine for a total 18 doses.</description>
    <arm_group_label>Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4</arm_group_label>
    <other_name>LY3022855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically or cytologically proven adenocarcinoma of the pancreas.&#xD;
&#xD;
          -  Patient's acceptance to have a core biopsy.&#xD;
&#xD;
          -  Presence of at least one measurable lesion.&#xD;
&#xD;
          -  Must not have metastatic disease.&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;20&#xD;
             mm with conventional techniques or as &gt;10 mm with spiral CT scan. See Section 10.1.2&#xD;
             for the evaluation of measurable disease.&#xD;
&#xD;
          -  Must have received last dose of stereotactic body radiotherapy no longer than 28 days&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Must have received last dose of chemotherapy at least 14 days or longer prior to entry&#xD;
             into the study.&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Patient's blood, kidney and liver function must within normal limits&#xD;
&#xD;
          -  Must use an acceptable form of birth control while on study.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently is participating or has participated in a study using any investigational&#xD;
             therapy within the past 28 days or is currently using an investigational device.&#xD;
&#xD;
          -  Major surgery 28 days prior to study entry excluding minor procedures (dental work,&#xD;
             skin biopsy, etc.), celiac plexus block, and biliary stent placement.&#xD;
&#xD;
          -  Used any systemic steroids, immunosuppressant medications and anti-neoplastic&#xD;
             treatment in the past 14 days.&#xD;
&#xD;
          -  Prior treatment with immunotherapy agents (including, but not limited to: IL-2,&#xD;
             interferon, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or&#xD;
             anti-CTLA-4 antibodies).&#xD;
&#xD;
          -  Used any growth factors including, but not limited to, granulocyte-colony stimulating&#xD;
             factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration.&#xD;
             Use of such agents while on study is also prohibited.&#xD;
&#xD;
          -  Received any prophylactic vaccine within 14 days of first dose of study drug or&#xD;
             received a live vaccine within 30 days of study treatment.&#xD;
&#xD;
          -  Currently have or have history of certain study-specified heart, liver, kidney, lung,&#xD;
             neurological, psychological, immune or other medical conditions.&#xD;
&#xD;
          -  History of any autoimmune disease: inflammatory bowel disease, (including ulcerative&#xD;
             colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis&#xD;
             (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g.,&#xD;
             Wegener's Granulomatosis), CNS or motor neuropathy considered to be of autoimmune&#xD;
             origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis).&#xD;
             Patients with thyroid disease will be allowed.&#xD;
&#xD;
          -  Has history of (non-infectious) pneumonitis that required steroids, history or&#xD;
             evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
          -  Has a pulse oximetry &lt; 92% on room air.&#xD;
&#xD;
          -  Evidence of ascites on imaging.&#xD;
&#xD;
          -  Requires the use of home oxygen.&#xD;
&#xD;
          -  Have known history of infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Have been diagnosed with another cancer in the past 5 years (except for superficial&#xD;
             bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not&#xD;
             requiring therapy)&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to GM-CSF, hetastarch, corn, dimethyl sulfoxide,&#xD;
             fetal bovine serum, trypsin (porcine origin), yeast or any other component of GVAX&#xD;
             pancreas vaccine.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Positive pregnancy test during the study.&#xD;
&#xD;
          -  Women sexually active with a fertile man and of childbearing potential unwilling or&#xD;
             unable to use an acceptable method to avoid pregnancy for the entire study and for up&#xD;
             to 120 days after the last dose of study drug.&#xD;
&#xD;
          -  Unwilling or unable to follow the study schedule for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana DeJesus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>antibody</keyword>
  <keyword>PD-1</keyword>
  <keyword>IMC-CS4</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>GVAX</keyword>
  <keyword>Borderline Resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

